Skip to main content

Table 1 Demographics and clinical characteristics of the 56 patients, categorized by responders and non-responders

From: Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

Characteristics

All patients

(n = 56)

Respondersa

(n = 8)

Non-responders

(n = 48)

P value

Sex

Male

31 (55%)

5

26

0.72

Female

25 (45%)

3

22

Age (years)

Median (range)

65 (43–91)

62 (44–74)

65 (43–91)

0.29

Race

White

49 (88%)

8

41

1.00

Black

3 (5%)

0

3

Asian

2 (3.5%)

0

2

Other

2 (3.5%)

0

2

Smoking

Never

10 (18%)

1

9

1.00

Former

27 (48%)

4

23

Current

19 (34%)

3

16

Histology

Adenocarcinoma

40 (71%)

6

34

0.59

Squamous cell carcinoma

9 (16%)

2

7

NSCLC NOSb

7 (13%)

0

7

  1. airRECIST1.1 and RECIST1.1 have resulted in the same 8 responders
  2. bNSCLC NOS = non-small-cell carcinoma not otherwise specified